Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Mr Michał Tendera
Mr Wojciech Wojakowski,
Atherosclerosis begins in childhood, as shown in necropsy studies (PDAY study, Bogulosa Heart Study) which demonstrated the presence of atherosclerotic lesions in children as young as 2 years of age.The clinical benefits of secondary prevention of coronary heart disease (CHD) have been widely recognised.
The concept of primary prevention is more complicated because the risk status of subjects without CHD can vary greatly. Indeed, effective primary prevention is dependent on reliable, sensitive and cost-effective methods of screening that will allow to identify high risk groups- i.e. subjects that will benefit most from the lowering of the CHD risk. Early identification of a high risk status is important because as atherosclerosis becomes clinically symptomatic, the global risk for further coronary events increases greatly, beyond the global risk factor clustering in comparison to asymptomatic subjects . According to the National Cholesterol Education Program (NCEP) and to the European Atherosclerosis Society, the positive history of premature CAD is defined as an incidence of CHD, stroke, sudden coronary death, the presence of angiographically evidenced coronary atherosclerosis or revascularisation procedures (PTCA or CABG) performed in one or two parents before the age of 65 years (mother) or 55 years (father) . The Framingham Heart Study investigators showed that familial history of premature CHD in a subject significantly increases his or her global risk independently from his or her basal risk factor status and is considered a predisposing risk factor of CHD. The extent to which familial predisposition enhances the global CHD risk is however poorly defined. The history of premature CHD in first-degree relatives was shown to be a more predictive CHD risk factor than hypertension, cigarette smoking and hypercholesterolemia. The reported frequency of CHD risk factors among children in this study was between 6,7% (boys aged 7-14 years) and 26,6% (boys aged 15-19 years). One of the most extensively investigated CHD risk factors is hypercholesterolemia. Children and adolescents with elevated cholesterol levels are prone to having hypercholesterolemia in adulthood and can easily be identified and adequately treated. However, there is the large group of children with normal lipid levels that have a high risk status because of the familial history of premature CHD. However, in groups of children without lipid disorders and other major CHD risk factors, it is important to find other biochemical correlates of CHD risk. No study so far exists to prove that the reduction of one non-traditional factor is independently associated with the reduction of the risk of CHD events. According to the recommendations published in Circulation, the levels of such risk factors (even more firmly established CRP) should not be used for monitoring the clinical benefit of the therapy [2-3].
None of the so-called non-traditional risk markers that have so far been proved to be of incremental prognostic value and independent of traditional risk markers in population of high risk children (ie. from families with history of premature CHD). Within these non-traditional risk markers, there isn’t yet one set of markers (endothelial damage markers, elastin-derived peptides, antioxidant enzymes) that seem to have stronger prognostic value than the others.
It has been shown that the endothelium’s vasomotor function can be adversely influenced by early life factors such as low birth weight . Therefore, it is likely that markers of the early atherosclerotic process are vasoactive and might be endothelium-associated substances. There are numerous biochemical correlates of atherosclerosis which are included into the conditional risk factors category - associated with the increased risk of CHD - however the magnitude of the causal link has yet to be documented [1-5]. The data on biochemical risk factors in children with familial history of CHD is sparse. The markers that allow insight into the endothelial function in vivo are presently widely investigated because they would facilitate the assessment of the global risk factor burden, including poorly defined factors.
In children with a high risk of CHD, the concentration of soluble endothelial adhesion molecule (ICAM-1) and von Willebrand factor were shown to be significantly higher in comparison to children without the familial history of premature CHD . This might reflect the increased recruitment of inflammatory cells into the subendothelial layer and reflect the extent of endothelial injury in atherosclerosis. Numerous large studies showed that the concentration of C-reactive protein (CRP) is a predictor of cardiovascular events in apparently healthy subjects. In healthy children, increased serum CRP levels are associated with a decreased endothelial vasodilatory function and an increased carotid artery intima-media thickness (IMT) which is a reliable surrogate for atherosclerosis. It seems that IMT is the currently most reliable noninvasive marker of preclinical atherosclerosis in high risk children with hypercholesterolemia and diabetes [7, 8]. The CRP levels are associated with body mass index in teenagers, so diet and lifestyle modification should reduce the CRP levels, but it's not sure if the risk reduction will be associated with the lowering of CRP or reduction of other metabolic abnormalities associated with obesity (eg. insulin resistance). The metabolism of the arterial connective tissue protein elastin seems to be different in high risk children – the turnover of elastin is increased, leading to an elevated concentration of proatherogenic elastin degradation products and to the presence of anti-elastin antibodies in the blood. The levels of antithrombotic prostacyclin (PGI2) and its metabolite 6 ketoPGF1a in children of parents who had acute myocardial infarction before the age of 45 years are significantly lower whereas the levels of prothrombotic and vasoconstrictive thromboxane A2 are higher than in healthy children . The activation of the immune system, evidenced by the presence of antibodies against heat shock protein (HSP60) reflecting a chronic inflammatory process may also play a role in the development of atherosclerosis in young individuals . Moreover, activity of antioxidant enzymes (catalase and glutathione peroxidase), selenium concentration and the total antioxidant status are significantly decreased in the blood of high risk children than in children without the familial history of premature CAD suggesting impaired scavenging of noxious free radicals . Few predominantly retrospective studies demonstrated altered concentrations of the above described biochemical soluble markers in high risk children in comparison to children without a history of premature CAD, yet they suggested that they might be useful in screening for the increased risk of CHD in children. This screening approach nevertheless needs validation. First, it must be confirmed that in large population-based prospective studies altered concentrations of such biochemical markers are indeed associated with an increased risk of coronary events in high-risk children - normal values in various age-groups has yet to be established and essays standardised anyway. Second, it should be proved that pharmacological or non-pharmacological prevention both normalises the levels of biochemical markers and reduces the risk of future CHD events to comparable levels of those of children from families without a history of premature CAD. Finally, the association of these non-traditional risk markers weaken in the presence of established risk factors, hence their prognostic value is probably limited to a population of children from high-risk families without traditional risk factors – it is important that the prognostic value of these factors be independent from and incremental to traditional risk factors.
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
To conclude, although the familial history of premature CAD is associated with biochemical and functional abnormalities of the endothelium in children, it seems that the widespread use of non-traditional markers for clinical purposes is premature and according to a Statement for Healthcare Professionals from the Centers for Disease Control and Prevention and the American Heart Association, there are no indications for routine measurements of CRP and other inflammatory markers for the assessement of CHD risk, at least in the adult population. Nonetheless, cardiologists treating adult patients with an early manifestation of coronary atherosclerosis should remember about the increased CHD risk of their children . Familial history which is a very strong risk factor is associated with metabolic and functional abnormalities of the endothelium and some markers of endothelial injury exist and are significantly altered in high risk children, but so far no clinical data exist to justify their use in general clinical practice. This may however change, since this field is being intensively investigated.
 Grundy SM, Pasternak R, Greenland P et. al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999;100:1481-1492. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10500053
 Myers RH, Kiely DK, Cupples LA et al. Parental history is an independent risk factor for coronary artery disease: the Framingham Study. Am Heart J 1990;120:963-969. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=2220549
 Rainwater DL, McMahan AC, Malcom GT et al. Lipid and Apolipoprotein Predictors of Atherosclerosis in Youth. Atheroscler Thromb Vasc Biol 1999;19:753-761. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10073983
 Leeson CPM, Whincup PH, Cook DG et al. Flow-mediated dilation in 9-11 year-old children. The influence of intrauterine and childhood factors. Circulation 1997;96:2233-2238. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9337195  Shah PK. Circulating markers of inflammation for vascular risk prediction. Are they ready for prime time. Circulation 2000;101:1758-1758. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10769272  Wojakowski W, Gminski J. Plasma levels of von Willebrand factor, endothelin-1, prostacyclin and thromboxane in children from families with high risk of premature coronary artery disease. Scand J Clin Lab Invest. 2001, 2001, 61, 317-23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11465346
 Järvisalo MJ, Harmoinen A, Hakanen M et al. Elevated Serum C-Reactive Protein Levels and Early Arterial Changes in Healthy Children. Arterioscler Thromb Vasc Biol. 2002;22:1323-1328. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12171795
 Martin H, Hu J, Gennser G et al. Impaired Endothelial Function and Increased Carotid Stiffness in 9-Year-Old Children With Low Birthweight. Circulation 2000;102:2739-2744 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11094041
 Mihai K, Peto J, Kolthay E et al. Balance of prostacyclin and thromboxane in offspring of parents with premature coronary arterial disease. Int J Cardiol 1992;35:13-18 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=1563873
 Knoflach M, Kiechl S, Kind M et al. Cardiovascular Risk Factors and Atherosclerosis in Young Males ARMY Study (Atherosclerosis Risk-Factors in Male Youngsters. Circulation. 2003;108:1064-1069. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12952827
 Wojakowski W., Gminski J, Wójcik A, Posielężna B, Francuz T. The plasma activity of antioxidant enzymes in children from families with high risk of premature coronary heart disease. Circulation. 2001, Suppl. 104, 17, I-2298. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11465346
 Pearson TA, Mensah GA, Alexander RW et al. Markers of Inflammation and Cardiovascular Disease Application to Clinical and Public Health Practice. A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12551878